» Articles » PMID: 10872460

Nuclear-receptor Ligands and Ligand-binding Domains

Overview
Publisher Annual Reviews
Specialty Biochemistry
Date 2000 Jun 29
PMID 10872460
Citations 67
Authors
Affiliations
Soon will be listed here.
Abstract

The determination of several structures of nuclear receptor ligand binding domains (LBD) has led to new insights into the mechanism of action of this very important class of receptors. This review describes and compares the different LBD structures and their relationship to the function of the nuclear receptors. The role of the ligand in the LBD structures and the implications of ligand structure on receptor activity are also discussed. Structural information regarding interactions between the LBD and coactivator proteins and the potential role of these interactions in ligand agonism and antagonism is reviewed. Different pathways for nuclear receptor signaling and the use of new ligands to investigate these pathways are also described.

Citing Articles

Comparative Evaluation and Profiling of Chemical Tools for the Nuclear Hormone Receptor Family 2.

Lewandowski M, Busch R, Marschner J, Merk D ACS Pharmacol Transl Sci. 2025; .

PMID: 40046426 PMC: 7617459. DOI: 10.1021/acsptsci.4c00719.


Site-specific O-GlcNAcylation of progesterone receptor (PR) supports PR attenuation of interferon stimulated genes (ISGs) and tumor growth in breast cancer.

Saunders H, Holloran S, Trinca G, Artigues A, Villar M, Tinoco J J Biol Chem. 2024; 300(11):107886.

PMID: 39395796 PMC: 11609360. DOI: 10.1016/j.jbc.2024.107886.


Safety Implications of Modulating Nuclear Receptors: A Comprehensive Analysis from Non-Clinical and Clinical Perspectives.

Rao M, McDuffie E, Srivastava S, Plaisted W, Sachs C Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065726 PMC: 11279859. DOI: 10.3390/ph17070875.


International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023.

Burris T, de Vera I, Cote I, Flaveny C, Wanninayake U, Chatterjee A Pharmacol Rev. 2023; 75(6):1233-1318.

PMID: 37586884 PMC: 10595025. DOI: 10.1124/pharmrev.121.000436.


Nuclear receptor ligand screening in an iPSC-derived in vitro blood-brain barrier model identifies new contributors to leptin transport.

Shi Y, Kim H, Hamann C, Rhea E, Brunger J, Lippmann E Fluids Barriers CNS. 2022; 19(1):77.

PMID: 36131285 PMC: 9494897. DOI: 10.1186/s12987-022-00375-3.